The Life Sciences team advised Scholar Rock (“SRRK”) on the closing of its initial public offering of 6,164,000 shares of common stock at the public offering price of $14.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 804,000 additional shares. The gross proceeds from the offering were approximately $86.3 million, before deducting underwriting discounts and commissions and estimated offering expenses.
Scholar Rock is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.
The Goodwin team was led by partners Kingsley Taft.
For more information on the offering, please read the press release.